135 related articles for article (PubMed ID: 38318230)
1. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States.
Layton JB; Peetluk L; Wong HL; Jiao Y; Djibo DA; Bui C; Lloyd PC; Gruber JF; Miller M; Ogilvie RP; Deng J; Parambi R; Song J; Weatherby LB; Lo AC; Matuska K; Wernecke M; Clarke TC; Cho S; Bell EJ; Seeger JD; Yang GW; Illei D; Forshee RA; Anderson SA; McMahill-Walraven CN; Chillarige Y; Amend KL; Anthony MS; Shoaibi A
Vaccine X; 2024 Jan; 16():100447. PubMed ID: 38318230
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study.
Ogilvie RP; Layton JB; Lloyd PC; Jiao Y; Djibo DA; Wong HL; Gruber JF; Parambi R; Deng J; Miller M; Song J; Weatherby LB; Peetluk L; Lo AC; Matuska K; Wernecke M; Bui CL; Clarke TC; Cho S; Bell EJ; Yang G; Amend KL; Forshee RA; Anderson SA; McMahill-Walraven CN; Chillarige Y; Anthony MS; Seeger JD; Shoaibi A
BMC Pediatr; 2024 Apr; 24(1):276. PubMed ID: 38671379
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
5. Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States.
Adams K; Rhoads JP; Surie D; Gaglani M; Ginde AA; McNeal T; Ghamande S; Huynh D; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hicks M; Hager DN; Ali H; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Lauring AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Chappell JD; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Lindsell CJ; Hart KW; Lester SN; Thornburg NJ; Park S; McMorrow ML; Patel MM; Tenforde MW; Self WH
medRxiv; 2022 Jun; ():. PubMed ID: 35734090
[No Abstract] [Full Text] [Related]
6. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
7. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
[TBL] [Abstract][Full Text] [Related]
9. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
MMWR Morb Mortal Wkly Rep; 2023 Mar; 71(53):1637-1646. PubMed ID: 36921274
[TBL] [Abstract][Full Text] [Related]
10. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
Riefolo F; Castillo-Cano B; Martín-Pérez M; Messina D; Elbers R; Brink-Kwakkel D; Villalobos F; Ingrasciotta Y; Garcia-Poza P; Swart-Polinder K; Souverein P; Saiz LC; Bissacco CA; Leache L; Tari M; Crisafulli S; Grimaldi L; Vaz T; Gini R; Klungel O; Martín-Merino E
Vaccine; 2023 Nov; 41(47):7007-7018. PubMed ID: 37858451
[TBL] [Abstract][Full Text] [Related]
14. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
[TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.
Adams K; Rhoads JP; Surie D; Gaglani M; Ginde AA; McNeal T; Talbot HK; Casey JD; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hager DN; Frosch AE; Exline MC; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Lauring AS; Khan A; Busse LW; Duggal A; Wilson JG; Chang SY; Mallow C; Kwon JH; Chappell JD; Halasa N; Grijalva CG; Lindsell CJ; Lester SN; Thornburg NJ; Park S; McMorrow ML; Patel MM; Tenforde MW; Self WH;
BMJ; 2022 Oct; 379():e072065. PubMed ID: 36220174
[TBL] [Abstract][Full Text] [Related]
16. Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Takhar H; Ogun OA; Simmons S; Zamparo JM; Tseng HF; Jodar L; McLaughlin JM
JAMA Netw Open; 2023 Jan; 6(1):e2251833. PubMed ID: 36662525
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
Paternina-Caicedo A; Quevedo DS; Ríos DS; Moyano D; Alvis-Guzmán N; Alviz-Zakzuk NR; Salcedo F; Moyano L; Ramírez-Suarez J; Smith AD; De la Hoz-Restrepo F
Vaccine; 2023 Oct; 41(42):6291-6299. PubMed ID: 37679278
[TBL] [Abstract][Full Text] [Related]
19. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
Sane Schepisi M
Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
